Hitachi forms nuclear medicine division
Japanese vendor Hitachi Medical of Tokyo has formed a new nuclearmedicine division to handle direct sales in North America of itsgamma cameras. The move culminates Hitachi's comeback in the modality,which began when Summit Nuclear stopped marketing the
Japanese vendor Hitachi Medical of Tokyo has formed a new nuclearmedicine division to handle direct sales in North America of itsgamma cameras. The move culminates Hitachi's comeback in the modality,which began when Summit Nuclear stopped marketing the Hitachiproducts following the merger of Summit and Sopha Medical (SCAN10/11/95).
Hitachi's Nuclear Medicine Products Division will be based inTwinsburg, OH, and will be a subsidiary of Hitachi Medical Corporationof America, which is based in Tarrytown, NY. Former Summit executiveGary Enos is general manager of the division.
At last month's Radiological Society of North America meeting,Hitachi displayed SpectraDigital V250 DSP, the company's variable-angledual-head gamma camera. The company also had panels on 511-keVcollimation and a work-in-progress Coincidence Detection Reconstruction(CDR) technique.
Hitachi is also developing a new nuclear medicine workstation,SpectraDigital 300SS, which is based on a Hewlett-Packard platformwith applications software developed in cooperation with MedasysDigital Systems. The computer is expected to be available earlythis year.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
